After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with a ...

Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 ...

Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in ...

Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein.

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and ...

Flagship CEO-partner and Ring CEO Tuyen Ong, M.D., will also be shifting to an advisory role in the new year, according to ...

Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas ...

Freshly public BioAge Labs has secured a multi-year partnership with Novartis that focuses on age-related diseases and ...

Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies. | Italian VC ...

Roche has begun rolling out a new diagnostics system that aims to bring the gold-standard accuracy of mass spectrometry to ...

Pruritus drug developer Cara Therapeutics kicked off the year halving its headcount, and the biotech has now found a new home ...